Letermovir

(Prevymis®)

Prevymis®

Drug updated on 11/13/2023

Dosage FormTablet (oral: 240 mg, 480 mg); Injection (intravenous: 240 mg/12 mL, 480 mg/24 mL)
Drug ClassCMV DNA terminase complex inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT).
  • Indicated for prophylaxis of CMV disease in adult kidney transplant recipients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R-])